August 17th 2025
Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.
Navigating CAR-T Therapy in RRMM: Patient Counsel and Managing AEs
December 5th 2023Explore the critical aspects of counseling patients on the expectations and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) associated with CAR-T therapy.
Available Options for CAR T-Cell Therapy in Patients With RRMM
November 30th 2023Dr Dhakal outlines the FDA-approved CAR T-cell therapy products for patients with multiple myeloma who have undergone at least four prior lines of treatment, emphasizing a focus on individualized decision-making when selecting patients for CAR-T.
Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma
November 23rd 2023A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.
Toxicity Management in Patients With RRMM Receiving Bispecific Antibodies
November 23rd 2023Drs Costa, Dhakal, and Cook discuss managing the unique toxicities of bispecific antibodies in patients with relapsed/refractory multiple myeloma such as infections requiring prophylaxis and supportive care, and quality-of-life complaints like taste changes and skin issues.
Cross Q&A: Role of Belantamab Mafodotin in MM
The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Teclistamab plus Nirogacestat in RRMM: The MAJESTEC-2 Study
November 16th 2023Drs Luciano Costa and Binod Dhakal discuss combining bispecific antibodies with gamma secretase inhibitors for the treatment of relapsed/refractory multiple myeloma, but trials show limited benefit and added toxicity; more promising are combinations with immunomodulators like isatuximab.